- Home
- Equipment
- switzerland
- drugs which target
Refine by
Drugs Which Target Equipment Supplied In Switzerland
8 equipment items found
Manufactured by:Advanced Accelerator Applications SA based inRueil-Malmaison Cedex, FRANCE
AAA brand names for [18F]-choline (FCH). ...
Manufactured by:Advanced Accelerator Applications SA based inRueil-Malmaison Cedex, FRANCE
AAA brand names for 6-fluoro-[18F]-L-DOPA, a DOPA analog. Neurology, ...
by:Orion Biotechnology Canada, Ltd. based inOttawa, SWITZERLAND
G Protein-Coupled Receptors (GPCRs) are involved in a wide range of physiological and pathological processes and represent a large class of drug targets accounting for >30% of all drugs on the market. These drugs, however, only cover 15% of the entire GPCR family, and many valuable receptors remain undrugged. In particular, GPCRs whose natural ligands are large peptides or small proteins are ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Allosteric modulators are an emerging class of orally available small molecule therapeutic agents that may offer a competitive advantage over classical ...
by:STALICLA based inGeneve, SWITZERLAND
STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches these patient subgroups with an NDD-targeted drug (or drug combination) by integrating and analyzing large omics data sets, including genomics, ...
Manufactured by:InterAx Biotech AG based inVilligen, SWITZERLAND
Our breakthrough platform combines systems biology, pharmacology, and artificial intelligence to accelerate the hit-to-lead process in GPCR drug discovery. InterAx is setting an industry example of how to better understand the biology of a disease and de-risk drug candidates. Instead of only leveraging large quantities of data with machine learning algorithms, we simultaneously incorporate ...
Manufactured by:EsoCap AG based inBasel, SWITZERLAND
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
by:CDR-Life based inSchlieren, SWITZERLAND
CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly cancer-targeted and drug-based immunotherapies against intracellular tumor antigens for treatment of a variety of solid tumor malignancies. In addition, the company has a superior trispecific BCMA therapy positioned for partnering as well as a ...